Search Results

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme’s ENHANZE® manufacturing methods that the Company provides to its current and future licensees.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the Goldman Sachs 45th Annual Global Healthcare conference.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.

Halozyme Therapeutics, Inc. announced the election of Mahesh Krishnan, M.D. to its Board of Directors.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the first quarter ended March 31, 2024, and provided an update on its recent corporate activities and outlook.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

Halozyme Therapeutics, Inc. announced that Roche received European Commission marketing authorization of OCREVUS® SC co-formulated with ENHANZE®, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.

Halozyme Therapeutics, Inc. today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences.

Halozyme Therapeutics, Inc. announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme’s ENHANZE® manufacturing methods that the Company provides to its current and future licensees.